Moderna Inc. ($MRNA) Stock Forecast: Up 11.9% Today

What is Moderna Inc.?

Moderna (MRNA) is a biotechnology company recognized for its mRNA technology, which gained significant attention during the COVID-19 pandemic for its vaccine development.

Why is Moderna Inc. going up?

MRNA stock is up 11.9% on Jun 26, 2026 18:01

• Moderna's stock surged over 14% today, reaching $68.23, driven by positive developments in its mRNA therapeutic pipeline, particularly the FDA advisory committee's endorsement of its flu vaccine, mFLUSIVA.
• The company's strategic restructuring into three commercial franchises and plans for manufacturing investment in Germany showcased its evolution beyond COVID-19, attracting momentum traders and boosting investor confidence.
• Despite the strong performance, concerns linger around the company's profitability challenges, as indicated by its GF Score™ of 58/100 and notable insider selling activity, warranting caution among Wall Street analysts despite the stock's impressive run.
• Moderna's outperformance compared to other vaccine stocks like Merck and Pfizer today underscores the market's positive reception of its pipeline news and revenue growth, positioning the company as a diversified mRNA platform player with promising prospects.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

Moderna (MRNA) Sees 14.2% Surge, Reaches $68.23

Moderna (MRNA) saw a significant stock price surge of 14.2%, reaching $68.23, driven by renewed investor confidence and positive developments in its mRNA therapeutic pipeline. Despite this growth, the company's GF Score™ of 58/100 indicates moderate quality with challenges in profitability, and there has been significant insider selling, raising mixed signals for investors.

https://www.gurufocus.com/news/8934511/moderna-mrna-sees-142-surge-reaches-6823

MRNA Stock Jumps As Flu Win And Pipeline Story Heat Up

Moderna Inc. (MRNA) stock surged over 11% following positive news regarding its mRNA vaccine pipeline, including a unanimous FDA advisory committee backing for its flu vaccine, mFLUSIVA. The company also unveiled a strategic restructuring into three commercial franchises and highlighted a broadened pipeline in oncology, autoimmune, and rare diseases. This, coupled with plans for manufacturing investment in Germany, signals Moderna's evolution beyond just COVID-19 to become a diversified mRNA platform company, attracting momentum traders.

https://stockstotrade.com/news/moderna-inc-mrna-news-2026_06_26-2/

Chip Rout Drags Nasdaq 100, Oil Sinks Below $69: Stock Market Today

On Friday, a significant sell-off in chipmakers and AI stocks impacted U.S. equities, pulling the Nasdaq 100 lower while the Dow Jones maintained gains. West Texas Intermediate crude oil also tumbled below $69, marking its worst monthly performance since March 2020. Conversely, software and defensive sectors saw rotation, with Moderna surging on pipeline news.

https://www.benzinga.com/markets/equities/26/06/60133015/semiconductor-chipmaker-stocks-fall-nasdaq-100-oil-crude-sinks-69-markets-friday

Moderna Is Up 13% Today: Is It Outperforming Other Vaccine Stocks Like Merck and Pfizer?

Moderna (MRNA) stock surged 14% to $68, significantly outperforming Merck (MRK) and Pfizer (PFE), which gained 2% each. This rally is attributed to an FDA advisory committee's unanimous endorsement of Moderna's flu vaccine and strong Q1 2026 revenue growth. Despite the impressive run and a 130% year-to-date gain, Wall Street analysts remain cautious, with a consensus price target of $43, well below current trading levels, and notable insider selling activity.

https://247wallst.com/investing/2026/06/26/moderna-is-up-13-today-is-it-outperforming-other-vaccine-stocks-like-merck-and-pfizer/

Biogen Jumps 6.1% Amid Sector-Wide Rally

Biogen Inc. shares experienced a 6.1% jump, closing at $214.35, as the biotech sector saw a broad rally. This increase reflects a sector-wide momentum with other peer companies like NTRA and MRNA also seeing significant gains, rather than a specific company-driven catalyst for Biogen. Investors are rotating back into biotech names, and future performance will depend on whether this trend is sustained or if company-specific developments emerge.

https://news.alphastreet.com/biogen-jumps-6-1-amid-sector-wide-rally/

Trending Today

McCormick & Company Incorporated ($MKC) Stock Forecast: Up 5.5% Today

Stryker Corporation ($SYK) Stock Forecast: Up 5.4% Today

Salesforce.com Inc ($CRM) Stock Forecast: Up 5.3% Today

Applied Materials Inc. ($AMAT) Stock Forecast: Down 6.7% Today

Cisco Systems Inc. ($CSCO) Stock Forecast: Down 5.0% Today

Fastly Inc. ($FSLY) Stock Forecast: Up 6.0% Today

Robinhood Inc. ($HOOD) Stock Forecast: Up 5.9% Today

Shopify Inc. Class A Subordinate ($SHOP) Stock Forecast: Up 5.4% Today

Caterpillar Inc. ($CAT) Stock Forecast: Down 5.1% Today

Lam Research Corporation ($LRCX) Stock Forecast: Down 5.3% Today

Moderna Inc. Price History

17.05.2026 - MRNA Stock was up 6.1%

• This company held an Investor Event Science Day to showcase its research and development programs, particularly emphasizing innovation using mRNA technology, which likely boosted investor confidence.
• Collaboration with the FDA for an mRNA flu vaccine and positive developments in the biopharma industry, along with growing interest in biotech IPOs and ongoing industry challenges, contributed to the positive sentiment.
• Stock gains were also influenced by new product releases and advancements in the company's pipeline, strengthening its market position.
• The bullish movement observed today can be attributed to a combination of positive developments, technological advancements, and investor confidence in the biopharma industry.

16.05.2026 - MRNA Stock was up 9.5%

• Moderna's stock saw a 9.5% surge due to favorable feedback from FDA staff regarding its flu vaccine candidate, mFlusiva, especially on its strong immune response in adults aged 65 and above. This positive development bolstered investor confidence in Moderna's vaccine projects.
• Initially met with some doubts from FDA scientists, the agreement between Moderna and the FDA on immunogenicity data pertaining to older adults before the upcoming advisory committee meeting on June 18th played a pivotal role in the stock's upward trajectory.
• The appointment of Ester Banque as Chief Commercial Officer and the expanded responsibilities of President Stephen Hoge indicate Moderna's strategic groundwork for potential product launches, such as flu and norovirus vaccines, supporting favorable market outlook towards the company.
• The regulatory process concerning Moderna's flu vaccine, with lingering uncertainties on its long-term safety and efficacy for specific demographics, will be a crucial determinant affecting the company's stock performance in the coming period.

17.05.2026 - MRNA Stock was up 10.8%

• Moderna's bullish movement today could be attributed to the anticipation and positive sentiment surrounding its upcoming Investor Event Science Day, where the company will showcase its research and development programs, emphasizing the potential of its mRNA platform in new therapeutic areas.
• The alignment with the FDA for its mRNA flu vaccine and the upcoming advisory committee meeting might have also contributed to investor optimism, reflecting confidence in Moderna's pipeline and regulatory progress.
• The broader industry trends, such as the surge in biotech IPOs and positive clinical results from other companies like Eli Lilly, could have created a favorable environment for Moderna's stock to thrive amidst growing interest in the biopharmaceutical sector.
• Overall, Moderna's strong performance today could be seen as a culmination of positive news flow, market dynamics, and investor expectations aligning in favor of the company's growth prospects.

17.05.2026 - MRNA Stock was up 6.3%

• Moderna's market uptick is linked to upbeat investor views following the Investor Event Science Day announcement. The event highlighted the company's research and development efforts, underscoring the potential of its mRNA platform in conjunction with AI and robotics.
• Collaboration with the FDA on its mRNA flu vaccine and the upcoming advisory committee meeting also played a role in the market's positive reaction, suggesting progress in Moderna's pipeline.
• The rise in biotech IPOs and ongoing biopharma sector developments may have contributed to the favorable climate for Moderna's stock, with investors expressing optimism about the industry's growth prospects.
• In general, Moderna's strategic actions, along with positive industry trends, likely drove today's bullish market performance.

26.05.2026 - MRNA Stock was up 13.9%

• The positive movement in Moderna's stock is driven by the FDA advisory committee's backing of its flu vaccine, fostering confidence among investors regarding the company's future.
• Robust revenue growth in Q1 further reinforces Moderna's market position and demonstrates its ability to meet its financial targets.
• Despite the significant surge and gains so far this year, analysts on Wall Street are exercising caution, with price targets below current trading levels, hinting at possible concerns of overvaluation.
• Analysts making adjustments to price targets and maintaining "Hold" recommendations reflect varied sentiments in the market, underscoring the importance for investors to evaluate Moderna's valuation and growth potential diligently before making any investment choices.

26.05.2026 - MRNA Stock was up 11.9%

• Moderna's stock surged over 14% today, reaching $68.23, driven by positive developments in its mRNA therapeutic pipeline, particularly the FDA advisory committee's endorsement of its flu vaccine, mFLUSIVA.
• The company's strategic restructuring into three commercial franchises and plans for manufacturing investment in Germany showcased its evolution beyond COVID-19, attracting momentum traders and boosting investor confidence.
• Despite the strong performance, concerns linger around the company's profitability challenges, as indicated by its GF Score™ of 58/100 and notable insider selling activity, warranting caution among Wall Street analysts despite the stock's impressive run.
• Moderna's outperformance compared to other vaccine stocks like Merck and Pfizer today underscores the market's positive reception of its pipeline news and revenue growth, positioning the company as a diversified mRNA platform player with promising prospects.

26.05.2026 - MRNA Stock was up 5.4%

• Moderna is strategically focusing on expanding its pipeline with new therapeutic modalities and commercial products as part of its plan to break even by 2028. This forward-looking strategy has positively influenced investor sentiment and the stock's performance.
• An adjustment of Moderna's price target by analysts at Jefferies indicates confidence in the company's future prospects, especially following a positive FDA panel recommendation regarding its mRNA-based influenza vaccine. This optimism likely contributed to the stock's bullish movement.
• The impending FDA approval of Moderna's mRNA-1010 flu vaccine has been a key driver of the stock's recent gains. Despite doubling in value this year, the company's promising pipeline, which includes a personalized cancer vaccine and an HIV vaccine, continues to attract investors.
• While financial metrics remain important, market interest in Moderna seems to be centered on its innovative capabilities, upcoming catalysts, and strategic growth initiatives, all of which have propelled the stock to new heights.

18.05.2026 - MRNA Stock was up 5.5%

• Moderna's bullish movement today could be attributed to the company considering acquiring BioNTech's German manufacturing plants. This strategic move not only expands Moderna's production capacity but also positions it favorably in the European market.
• Additionally, the FDA clearance for Beam Therapeutics' BEAM-304 PKU gene-editing trial may have indirectly boosted Moderna's stock, as it highlights the advancements in genetic therapies within the biotech sector.
• The FDA scrutiny of Moderna's mRNA flu vaccine could have also impacted the stock positively, as it demonstrates the company's commitment to expanding its vaccine portfolio beyond COVID-19 solutions.
• Overall, Moderna's proactive approach towards acquisitions, clinical trials, and vaccine development seems to have resonated well with investors, driving the bullish movement in its stock price today.

18.05.2026 - MRNA Stock was up 8.0%

• Moderna's bullish movement can be attributed to the positive news surrounding its mRNA flu vaccine facing FDA scrutiny for approval in older adults. This potential approval would mark a significant milestone for the company, especially in the competitive flu vaccine market.
• The anticipation of Moderna entering the flu vaccine market with its mRNA technology, competing with traditional vaccine companies like Sanofi and GSK, has likely sparked investor optimism and contributed to the bullish trend.
• Investors may view Moderna's innovative approach to vaccine development and its potential expansion into new markets as a positive sign for the company's growth prospects, driving the stock price higher.
• The news of Moderna's mRNA flu vaccine progress overshadowed other headlines in the biotechnology sector, keeping the focus on the company's promising developments and future potential.

23.05.2026 - MRNA Stock was up 6.5%

• Following a positive outcome from an FDA advisory committee vote on the benefit-risk profile of their seasonal flu vaccine, mRNA-1010, Moderna's stock witnessed a significant rise. This development has bolstered investor confidence in the company's vaccine portfolio.
• The market's response to Moderna's recent announcement contrasts with another company's stock decline, emphasizing the importance of regulatory approvals and product advancements in shaping stock performance.
• Moderna's stock upsurge mirrors investors' confidence in its growth potential, driven by its mRNA technology and upcoming product launches. It signifies a strong market belief in Moderna's capacity to provide innovative healthcare solutions.

22.05.2026 - MRNA Stock was down 5.2%

• Confirmation of Moderna's mRNA flu vaccine, mRNA-1010, passing the FDA Advisory Committee meeting is viewed positively, notwithstanding concerns about weak operational performance and high valuation.
• Leerink Partners' adjustment of the price target and maintenance of an "Underperform" rating are seen as contributing to the prevailing negative sentiment.
• Despite a recent 6-day streak of gains and a significant increase in market capitalization, worries regarding the company's financial health and valuation being deemed "Very Unattractive" may have overshadowed any positive trend.
• The $2.25 billion settlement with Roivant Sciences could have adversely affected Moderna's stock, despite providing legal clarity, as investors might be wary of its implications on Moderna's finances and future prospects.

25.05.2026 - MRNA Stock was down 5.5%

• Today's bearish movement for Moderna could be due to profit-taking by investors following the company's Science Day event, where advancements in its mRNA pipeline were showcased without any major breakthroughs or immediate revenue-generating milestones being announced.
• The market's negative reaction may stem from the absence of near-term commercial growth catalysts, as Moderna highlighted a long-term innovation strategy across multiple therapeutic areas like cancer and autoimmune diseases.
• Investor caution might be influenced by the high expectations set by Moderna in diversifying its pipeline and expanding its mRNA platform. This caution has led to a sell-off as investors await more concrete clinical data and revenue projections.